Verenium Corporation to Present at the BIO CEO & Investor Conference
Share:
CAMBRIDGE, Mass., Feb. 6 - Verenium Corporation (NASDAQ:VRNM), a leading developer of cellulosic ethanol technology and a pioneer in the development of high-performance specialty enzymes, announced today that William H. Baum, Verenium's Executive Vice President, Business Development and General Manager, Specialty Enzyme Business Unit, will present at the upcoming BIO CEO & Investor Conference. The presentation is scheduled to begin at 11:45 a.m. ET on Wednesday, February 13, and will take place at the Waldorf Astoria Hotel in New York, NY.
More information about this event, including a live webcast, may be accessed by visiting the "Investors" section of Verenium's website at www.verenium.com/. A webcast replay will be available approximately one hour after the live webcast ends and will be accessible for one month following the conference.
About Verenium
Verenium Corporation is a leader in the development and commercialization of cellulosic ethanol, an environmentally-friendly and renewable transportation fuel, as well as high-performance specialty enzymes for applications within the biofuels, industrial, and health and nutrition markets. The Company possesses integrated, end-to-end capabilities in pre-treatment, novel enzyme development, fermentation, engineering, and project development and is moving rapidly to commercialize its proprietary technology for the production of ethanol from a wide array of feedstocks, including sugarcane bagasse, dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for biofuels, a multitude of large-scale industrial opportunities exist for the Company for products derived from the production of low-cost, biomass-derived sugars.
Verenium's Specialty Enzyme business harnesses the power of enzymes to create a broad range of specialty products to meet high-value commercial needs. Verenium's world class R&D organization is renowned for its capabilities in the rapid screening, identification, and expression of enzymes -- proteins that act as the catalysts of biochemical reactions.
Verenium operates one of the nation's first cellulosic ethanol pilot plants, an R&D facility, in Jennings, Louisiana and expects to achieve mechanical completion of a 1.4 million gallon-per-year, demonstration-scale facility to produce cellulosic ethanol by the end of the first quarter of 2008. In addition, the Company's process technology has been licensed by Tokyo-based Marubeni Corp. and Tsukishima Kikai Co., LTD and has been incorporated into BioEthanol Japan's 1.4 million liter-per-year cellulosic ethanol plant in Osaka, Japan -- the world's first commercial-scale plant to produce cellulosic ethanol from wood construction waste. For more information on Verenium, visit www.verenium.com/.
FCMN Contact: kelly.lindenboom@verenium.com
Source: Verenium Corporation
CONTACT: Kelly Lindenboom, Vice President, Corporate Communications of Verenium Corporation, +1-617-674-5335, kelly.lindenboom@verenium.com
Web site: http://www.verenium.com/
